Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more
Dr. Reddy's Laboratories Limited - Asset Resilience Ratio
Dr. Reddy's Laboratories Limited (RDDA) has an Asset Resilience Ratio of 11.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Dr. Reddy's Laboratories Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dr. Reddy's Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €59.91 Billion | 11.05% |
| Total Liquid Assets | €59.91 Billion | 11.05% |
Asset Resilience Insights
- Moderate Liquidity: Dr. Reddy's Laboratories Limited has 11.05% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Dr. Reddy's Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Dr. Reddy's Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Dr. Reddy's Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 8.77% | €43.25 Billion | €492.99 Billion | -10.42pp |
| 2024-03-31 | 19.19% | €74.36 Billion | €387.52 Billion | +0.30pp |
| 2023-03-31 | 18.88% | €60.97 Billion | €322.85 Billion | +8.94pp |
| 2022-03-31 | 9.95% | €29.51 Billion | €296.65 Billion | +2.51pp |
| 2021-03-31 | 7.44% | €19.74 Billion | €265.49 Billion | -2.76pp |
| 2020-03-31 | 10.20% | €23.69 Billion | €232.24 Billion | +0.21pp |
| 2019-03-31 | 9.99% | €22.53 Billion | €225.43 Billion | +1.87pp |
| 2018-03-31 | 8.12% | €18.33 Billion | €225.60 Billion | +1.63pp |
| 2017-03-31 | 6.49% | €14.27 Billion | €219.82 Billion | -- |